RT Journal Article
T1 Pharmacological Extracts and Molecules from Virola Species: Traditional Uses, Phytochemistry, and Biological Activity
A1 González Rodríguez, María
A1 Ruiz Fernández, Clara
A1 Vera, Francisco
A1 Ait Eldjoudi, Djedjiga
A1 Ramadan Farrag Abdel Hafez, Yousof
A1 Cordero Barreal, Alfonso
A1 Pino Mínguez, Jesús
A1 Lago Paz, María Francisca
A1 Campos Toimil, Manuel
A1 Carvalho, Glaucimeire Rocha
A1 Pereira, Thiago Melo Costa
A1 Gualillo, Oreste
K1 Myristicaceae
K1 Pharmacology
K1 Phytotherapy
K1 Virola surinamensis
K1 Virola sebifera
K1 Resin
K1 Essential oil
K1 Flavonoid
K1 Lignan
K1 Alkaloid
AB Virola is the largest genus of Myristicaceae in America, comprising about 60 species of medium-sized trees geographically spread from Mexico to southern Brazil. The plant species of this genus have been widely used in folk medicine for the treatment of several ailments, such as rheumatic pain, bronchial asthma, tumors in the joints, intestinal worms, halitosis, ulcers, and multiple infections, due to their pharmacological activity. This review presents an updated and comprehensive summary of Virola species, particularly their ethnomedicinal uses, phytochemistry, and biological activity, to support the safe medicinal use of plant extracts and provide guidance for future research. The Virola spp.’s ethnopharmacology, including in the treatment of stomach pain and gastric ulcers, as well as antimicrobial and tryponosomicidal activities, is attributable to the presence of a myriad of phytoconstituents, such as flavonoids, tannins, phenolic acids, lignans, arylalkanones, and sitosterol. Hence, such species yield potential leads or molecular scaffolds for the development of new pharmaceutical formulations, encouraging the elucidation of not-yet-understood action mechanisms and ascertaining their safety for humans
PB MDPI
YR 2021
FD 2021
LK http://hdl.handle.net/10347/24479
UL http://hdl.handle.net/10347/24479
LA eng
NO Molecules 2021, 26(4), 792; https://doi.org/10.3390/molecules26040792
NO This work was supported by Xunta de Galicia (Servizo Galego de Saude, SERGAS), through a research-staff contract (ISCIII/SERGAS) to O.G. and F.L., who are Staff Personnel (I3SNS stable Researcher); by Instituto de Salud Carlos III (ISCIII) and by FEDER through a “Sara Borrell” Researcher contract to V.F. (CD16/00111); and a predoctoral research scholarship to C.R.-F. (Exp.18/00188). M.G.-R. is a recipient of a predoctoral contract funded by Xunta de Galicia (IN606A-2020/010). A.C.-B. is a recipient of a predoctoral contract funded by Secretaría de Estado de Universidades, Investigación, Desarrollo e Innovación, Ministerio de Universidades (FPU2018-04165). G.R.C. is a doctoral student of the Coordination for the Improvement of Higher Education Personnel (CAPES) with a doctoral scholarship (Finance Code 001). T.M.C.P. is a Research Productivity Fellow of the National Council for Scientific and Technological Development (CNPq), Brazil (TMCP 309277/2019-1). O.G. is a member of the RETICS Programme (RD16/0012/0014) (RIER: Red de Investigación en Inflamación y Enfermedades Reumáticas) via ISCIII and FEDER. F.L. is a member of CIBERCV (Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares). ISCIII and FEDER also support O.G. and J.P. (PI17/00409 and PI20/00902). This work was supported by the Research Executive Agency of the European Union in the framework of the MSCA-RISE Action of the H2020 Programme (project number, 734899), and Xunta de Galicia, Consellería de Educación, Universidade e Formación Profesional, and Consellería de Economía, Emprego e Industria (GAIN) (GPC IN607B2019/10), supported O.G.
DS Minerva
RD 24 abr 2026